This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meyer, K.
Right arrow Articles by Ray, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meyer, K.
Right arrow Articles by Ray, R.

 Previous Article  |  Next Article 

Journal of Virology, March 2002, p. 2150-2158, Vol. 76, No. 5
0022-538X/02/$04.00+0     DOI: 10.1128/jvi.76.5.2150-2158.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Complement-Mediated Enhancement of Antibody Function for Neutralization of Pseudotype Virus Containing Hepatitis C Virus E2 Chimeric Glycoprotein

*** Keith Meyer,1 Arnab Basu,1 Craig T. Przysiecki,2 L. Martin Lagging,3 Adrian M. Di Bisceglie,1 Anthony J. Conley,2 and Ranjit Ray1,4*

Departments of Internal Medicine,1 Molecular Microbiology and Immunology, Saint Louis University, St. Louis, Missouri,4 Department of Virus and Cell Biology, Merck Research Laboratories, West Point, Pennsylvania,2 Department of Infectious Diseases, Göteborg University, Göteborg, Sweden3

Received 1 October 2001/ Accepted 15 November 2001

We previously reported a number of features of hepatitis C virus (HCV) chimeric glycoproteins related to pseudotype virus entry into mammalian cells. In this study, pseudotype virus was neutralized by HCV E2 glycoprotein-specific antibodies and infected human sera. Neutralization (50% reduction of pseudotype virus plaque formation) was observed with two human immunoglobulin G1 monoclonal antibodies (MAbs) at concentrations of between 2.5 and 10 µg/ml. A hyperimmune rabbit antiserum to an E2 hypervariable region 1 (HVR1) mimotope also exhibited an HCV E2 pseudotype virus neutralization titer of ~1/50. An E1 pseudotype virus used as a negative control was not neutralized to a significant level (<1/10) by these MAbs or rabbit antiserum to E2 HVR1. Since HCV probably has a lipid envelope, the role of complement in antibody-mediated virus neutralization was examined. Significant increases in the neutralization titers of the human MAbs (~60- to 160-fold higher) and rabbit antiserum to HVR1 mimotopes (~10-fold higher) were observed upon addition of guinea pig complement. Further, these studies suggested that complement activation occured primarily by the classical pathway, since a deficiency in the C4 component led to a significant decrease in the level of virus neutralization. This same decrease was not observed with factor B-deficient complement. We also determined that 9 of 56 HCV-infected patient sera (16%) had detectable pseudotype virus neutralization activity at serum dilutions of between 1/20 and 1/50 and that complement addition enhanced the neutralization activity of some of the HCV-infected human sera. Taken together, these results suggest that during infection, HCV E2 glycoprotein induces a weak neutralizing antibody response, that those antibodies can be measured in vitro by the surrogate pseudotype virus plaque reduction assay, and that neutralization function can be augmented by complement.

* Corresponding author. Mailing address: Division of Infectious Diseases and Immunology, Saint Louis University, 3635 Vista Ave., St. Louis, MO 63110. Phone: (314) 577-8648. Fax: (314) 771-3816. E-mail: rayr{at}slu.edu.

Journal of Virology, March 2002, p. 2150-2158, Vol. 76, No. 5
0022-538X/02/$04.00+0     DOI: 10.1128/jvi.76.5.2150-2158.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Meyer, K., Ait-Goughoulte, M., Keck, Z.-Y., Foung, S., Ray, R. (2008). Antibody-Dependent Enhancement of Hepatitis C Virus Infection. J. Virol. 82: 2140-2149 [Abstract] [Full Text]  
  • Tani, H., Komoda, Y., Matsuo, E., Suzuki, K., Hamamoto, I., Yamashita, T., Moriishi, K., Fujiyama, K., Kanto, T., Hayashi, N., Owsianka, A., Patel, A. H., Whitt, M. A., Matsuura, Y. (2007). Replication-Competent Recombinant Vesicular Stomatitis Virus Encoding Hepatitis C Virus Envelope Proteins. J. Virol. 81: 8601-8612 [Abstract] [Full Text]  
  • Basu, A., Kanda, T., Beyene, A., Saito, K., Meyer, K., Ray, R. (2007). Sulfated Homologues of Heparin Inhibit Hepatitis C Virus Entry into Mammalian Cells. J. Virol. 81: 3933-3941 [Abstract] [Full Text]  
  • Ramos-Casals, M., Brito-Zeron, P., Yague, J., Akasbi, M., Bautista, R., Ruano, M., Claver, G., Gil, V., Font, J. (2005). Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. Rheumatology (Oxford) 44: 89-94 [Abstract] [Full Text]  
  • Meyer, K., Beyene, A., Bowlin, T. L., Basu, A., Ray, R. (2004). Coexpression of Hepatitis C Virus E1 and E2 Chimeric Envelope Glycoproteins Displays Separable Ligand Sensitivity and Increases Pseudotype Infectious Titer. J. Virol. 78: 12838-12847 [Abstract] [Full Text]  
  • Basu, A., Beyene, A., Meyer, K., Ray, R. (2004). The Hypervariable Region 1 of the E2 Glycoprotein of Hepatitis C Virus Binds to Glycosaminoglycans, but This Binding Does Not Lead to Infection in a Pseudotype System. J. Virol. 78: 4478-4486 [Abstract] [Full Text]  
  • Op De Beeck, A., Voisset, C., Bartosch, B., Ciczora, Y., Cocquerel, L., Keck, Z., Foung, S., Cosset, F.-L., Dubuisson, J. (2004). Characterization of Functional Hepatitis C Virus Envelope Glycoproteins. J. Virol. 78: 2994-3002 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»